

**HOW  
PHARMACEUTICAL  
SYSTEMS  
ARE ORGANIZED  
IN ASIA AND THE PACIFIC**



**HOW  
PHARMACEUTICAL  
SYSTEMS  
ARE ORGANIZED  
IN ASIA AND THE PACIFIC**

© World Health Organization/Organisation for Economic Co-operation and Development 2018

ISBN 978 92 9061 848 5

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules>).

**Suggested citation.** How pharmaceutical systems are organized in Asia and the Pacific. Manila: World Health Organization Regional Office for the Western Pacific; 2018. Licence: CC BY-NC-SA 3.0 IGO.

**Cataloguing-in-Publication (CIP) data.** 1. Asia. 2. Pharmaceutical preparations – economics, supply and distribution. I. World Health Organization Regional Office for the Western Pacific II. Organisation for Economic Co-operation and Development. (NLM Classification: QV 736)

**Sales, rights and licensing.** To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

For WHO Western Pacific Regional Publications, request for permission to reproduce should be addressed to Publications Office, World Health Organization, Regional Office for the Western Pacific, P.O. Box 2932, 1000, Manila, Philippines, Fax. No. (632) 521-1036, email: [wpropuballstaff@who.int](mailto:wpropuballstaff@who.int)

**Third-party materials.** If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

**General disclaimers.** The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

**WHO/OECD Joint Disclaimer:**

The opinions expressed and arguments employed herein are solely those of the authors and do not necessarily reflect the official views of the OECD or of its member countries or of the World Health Organization.

This document, as well as any data and map included herein are without prejudice to the status of or sovereignty over any territory, to the delimitation of international frontiers and boundaries and to the name of any territory, city or area.

# CONTENTS

---

<b>Executive summary .....</b>	<b>1</b>
<b>Introduction .....</b>	<b>2</b>
<b>Socio-economics .....</b>	<b>3</b>
<b>Human resources .....</b>	<b>3</b>
<b>Health expenditure .....</b>	<b>4</b>
<b>Pharmaceutical expenditure .....</b>	<b>4</b>
<b>Pharmaceutical regulation and pricing .....</b>	<b>6</b>
<b>Pharmaceutical procurement and reimbursement .....</b>	<b>6</b>
<b>Country profiles .....</b>	<b>7</b>



## EXECUTIVE SUMMARY

---

There are important differences in the markets for medicines in countries in Asia and the Pacific in this study. These are mainly due to the political, financial and regulatory environments as well as characteristics of the pharmaceutical manufacturing industry. However, all countries face the test of transition brought about by demographic changes, shifting epidemiological trends and increasing inequities, among others. As with other regions of the world, a characteristic of lower- and upper-middle-income countries is that pharmaceuticals account for a high proportion of health expenditures. Medicines account for a larger share of the health budgets in resource-constrained countries.

Pharmaceutical systems are complex and involve several intermediaries between medicines manufacturers and consumers. This suggests the need for better coordination among various agencies and relevant stakeholders involved. The intricate pharmaceutical landscape demands a better understanding of how pharmaceutical markets are organized, regulated and financed to foster policies aimed at achieving universal and equitable access to essential medicines.

Achieving equitable access to affordable, safe, efficacious and quality medicines through sound pharmaceutical policies, programmes and other interventions has remained a continuing challenge at all levels of health system strengthening for countries, with some performing better than others. This reality is even more pronounced in countries that are currently working towards universal health coverage where a large part of pharmaceutical spending is still out of pocket.

# INTRODUCTION

**Medicines, together with other health technologies, are one of the building blocks of a health system. Without them, it is impossible to achieve desirable health outcomes for individual patients and communities.**

As countries make further progress towards universal health coverage, essential medicines, more than ever, are crucial to achieving health and inclusive socioeconomic development. Sustainable Development Goal target 3.8 mentions the importance of “access to safe, effective, quality and affordable essential medicines and vaccines for all” as a central component of universal health coverage.

Access to essential medicines encompasses quality, safety and efficacy of drugs, as well as their availability, affordability and appropriate use. However, improving access to quality-assured essential medicines is not an end in itself. It is a means to improving health status, promoting well-being and achieving equity across populations. Demographic, epidemiological and economic transitions continue to generate major challenges for essential medicines.

Addressing issues around access to medicines requires a comprehensive understanding of how pharmaceutical systems are organized and function. This report presents profiles of 14 countries in Asia and the Pacific – Australia, Brunei Darussalam, Cambodia, China, Indonesia, Republic of Korea, Lao People’s Democratic Republic, Malaysia, Mongolia, New Zealand, Philippines, Singapore, Thailand and Viet Nam – that outline resources, structures and processes relating to ensuring availability and accessibility of pharmaceuticals in specific country settings and their interactions with the health-care system. The report represents an outcome of the activities of the Asia Pacific Network on Access to Medicines under Universal Health Coverage, a joint initiative by the WHO Regional Office for the Western Pacific, the Organisation for Economic Co-operation and Development (OECD) and the OECD Korea Policy Centre, with the support of the WHO Collaborating Centre for Health Systems and Financing at Seoul National University.



## SOCIO-ECONOMICS

---

Countries featured in this report range from Brunei Darussalam with a population of less than half a million to China with 1.36 billion inhabitants. The median life expectancy at birth across countries in this study is 75 years. The Lao People's Democratic Republic (64 years), Mongolia (68 years) and the Philippines (69 years) show a life expectancy at birth lower than that of the world population (71.4 years) and much lower than that of OECD countries (80.6 years). Differences in life expectancy across countries may be attributed to differences in income levels, living standards, lifestyles, education and accessibility of quality health services.

Across countries, the highest proportions of children aged below 15 years were observed in the Philippines (32.0%) and Cambodia (31.0%), whereas the lowest proportions were reported in the Republic of Korea (15.0%), Singapore (16.0%) and China (16.6%). The highest proportion of people aged over 60 years (20.0%) was recorded in Australia and New Zealand. Of note is that the proportion of people aged over 60 years is expected to increase significantly in the coming years, which can lead to an increased burden on those of working age to sustain spending for a range of services, including health, for an ageing population.

In terms of gross domestic product (GDP) per capita, the countries featured in this report include high-income countries – Singapore (\$ 82 208.90 per capita), Brunei Darussalam (\$ 67 131.80), Australia (\$ 46 244.10), New Zealand (\$ 37 340.00) and the Republic of Korea (\$ 34 321.60); upper-middle income countries – Malaysia (\$ 24 951.10), Thailand (\$ 15 346.70) and China (\$ 13 166.70); and lower-middle income countries – Mongolia (\$ 11 945.70), Indonesia (\$ 10 517.00), the Philippines (\$ 6 982.40), Viet Nam (\$ 5 525.80), the Lao People's Democratic Republic (\$ 5 278.20) and Cambodia (\$ 3 228.40). While GDP is a direct measure of economic production, it is also an indirect measure of economic well-being of a country.

## HUMAN RESOURCES

---

Australia has the highest number of physicians per 10 000 population (35.2), followed by the Lao People's Democratic Republic (29), Mongolia (28.4) and New Zealand (28.4). The Republic of Korea (14.6 per capita) has the highest number of doctor consultations per capita per year, followed by Australia (7.6 per capita), Mongolia (6.1 per capita) and China (5.4 per capita). Across OECD countries, on average 34 doctors per 10 000 population are reported. They guarantee 6.9 consultations per capita per year. The number of pharmacists per 1000 population is consistently low, from lower-middle-income (Cambodia, 0.14) to high-income countries (Brunei Darussalam, 0.17).

The Republic of Korea (10.3 per 1000 population) has the highest number of hospital beds, while Cambodia (0.7 per 1000 population) and Indonesia (0.6 per 1000 population) reported the lowest numbers. On average, OECD countries report 4.7 beds per 1000 population. The health system capacity and utilization of health-care services are correlated with available providers of services. Lower utilization of health-care services may suggest scarcity of resources, including human resources.


# HEALTH EXPENDITURE

Total health expenditure (THE) per capita shows a significant variation across the countries in the study, with the highest level reported in Australia (\$ 4357.00) and the lowest in the Lao People's Democratic Republic (\$ 35.50). THE as a share of GDP is highest in high-income countries such as Australia (10.0%), New Zealand (9.4%) and the Republic of Korea (7.4%), with the exception of Singapore (4.3%) and Brunei Darussalam (1.8%). For comparison, OECD countries spend on average 9% of GDP on health.

The share of government in total health spending varies from as high as 93.8% in Brunei Darussalam to as low as 18.9% in China, whereas out-of-pocket spending accounts for more than half of the THE in Cambodia (74.2%), the Philippines (53.7%) and the Lao People's Democratic Republic (52.6%). Out-of-pocket spending accounts for a much greater share of health expenditures in lower-middle-income countries than in high-income countries. Some countries have social health insurance systems which constitute a significant portion of THE, such as the Republic of Korea (42.9%), China (37.7%) and Viet Nam (24.07%).

# PHARMACEUTICAL EXPENDITURE


A large variation in pharmaceutical spending is observed across countries in the study. Per capita pharmaceutical spending ranges from \$ 27.3 in the Lao People's Democratic Republic and \$ 683.5 in Australia (Figure 1).




**Figure 1**  
Pharmaceutical expenditure per capita, international dollars (US\$ Purchasing Power Parity), 2014

\* data provided by the country  
Source: WHO Global Health Observatory 2016, OECD Health Statistics

Pharmaceutical spending as a share of THE ranges from 9.7% in New Zealand to 44% in Cambodia (Figure 2). Lower- and upper-middle-income countries have a higher total pharmaceutical expenditure (TPE) as a share of THE when compared to high-income countries. Across OECD countries, pharmaceutical spending represents on average 16% of total health spending.



The contribution of public and private sources to financing TPE varies greatly across countries as well. Countries that have a significantly higher public sector share are either high-income (Brunei Darussalam, New Zealand, Republic of Korea and Australia) or upper-middle income countries (Thailand and Malaysia). Countries that have a significantly higher private sector share are lower-middle-income countries, such as Indonesia (85.7%), the Philippines (85.0%), Viet Nam (83.5%), the Lao People's Democratic Republic (83.5%), Cambodia (77.5%) and Mongolia (74.0%) (Figure 3).



## PHARMACEUTICAL REGULATION AND PRICING

---

All countries have existing regulatory authority for pharmaceuticals as well as key legislations. Except for Singapore, all have a formal National Medicines Policy. In terms of pricing, not all countries have a dedicated agency that sets or controls the price of pharmaceutical products, such as in Brunei Darussalam, Cambodia, Mongolia and Singapore. In these countries, pricing of pharmaceuticals in the public sector is not regulated. The pricing of pharmaceuticals in the private sector is regulated only in Indonesia, the Philippines and Viet Nam.

Internal price referencing is not used in Indonesia, the Republic of Korea, Mongolia and Singapore. External price referencing is not used in Indonesia, Mongolia, New Zealand and Singapore. Except for Australia, Brunei Darussalam and Singapore, there is value-added tax on medicines in countries in the study ranging from 5% in Viet Nam to 17% in China.

## PHARMACEUTICAL PROCUREMENT AND REIMBURSEMENT

---

All countries have a dedicated agency that selects pharmaceuticals for procurement and reimbursement, while only Brunei Darussalam, Cambodia and Indonesia do not have an organization that is tasked to conduct health technology assessment. Countries have varying numbers of products in their Essential Medicines List, Procurement List and Reimbursement List.

## COUNTRY PROFILES

---

# Pharmaceutical System

# AUSTRALIA


## SOCIOECONOMICS<sup>1,5</sup>

**24 127 200**  
Population

**83 years**  
Life Expectancy at Birth



**20%**  
Percentage of Adults Aged over 60 Years



**19%**  
Percentage of Children Aged below 15 Years

**US\$ 46 244.1**  
GDP / Capita (PPP)

## HUMAN RESOURCES<sup>2,3,5</sup>



**35.2**  
per 10 000 population

No. of Physicians



**0.9**  
per 1000 population

No. of Pharmacists



**3.8**  
per 1000 population

Hospital Beds




**7.6**  
per capita


Doctor Consultations

## HEALTH EXPENDITURE<sup>4,5</sup>


**US\$ 4357.3**  
Total Health Expenditure / Capita (PPP)



Total Health Expenditure as a Share of GDP




Public vs Private Share of Total Health Expenditure




Composition of Total Health Expenditure

## PHARMACEUTICAL EXPENDITURE<sup>3</sup>

**US\$ 683.5**  
Total Pharmaceutical Expenditure / Capita (PPP)



Pharmaceutical Expenditure as a Share of Total Health Expenditure / Capita



Public vs Private Share of Total Pharmaceutical Expenditure

## PHARMACEUTICAL REGULATION

Regulatory Authority for Pharmaceuticals  
Therapeutic Goods Administration

Pharmaceutical Legislation  
National Health Act 1953

National Medicines Policy  
Non-legislative National Medicines Policy 2000

## PRICING

Agency that Sets Price  
Department of Health

Pricing Regulation in the Public Sector **YES**

Pricing Regulation in the Private Sector **YES<sup>a</sup>**

Free Pricing?

**NO**

Price Negotiations?

**YES**

External Price Referencing?

**YES**

Internal Price Referencing?

**YES**

VAT on Medicines

**NO**

## PROCUREMENT / REIMBURSEMENT

Body Responsible for Selection of Products for Public Procurement/Reimbursement  
Pharmaceutical Benefits Advisory Committee

**19 786**  
No. of Registered Medicines

Body Responsible for Health Technology Assessment  
Pharmaceutical Benefits Advisory Committee


No data available  
No. of Products on Essential Medicines List

No data available  
No. of Products on Procurement List

**5200**  
No. of Products on Reimbursement List

<sup>a</sup> For medicines included in the Pharmaceutical Benefits Scheme

# Pharmaceutical System Flowchart



## REFERENCES

- World health statistics (2015) [online database]. Geneva: World Health Organization ([http://www.who.int/gho/publications/world\\_health\\_statistics/2015/en/](http://www.who.int/gho/publications/world_health_statistics/2015/en/), accessed 25 November 2016).
- Pharmacy Board of Australia (2015). Statistics [website]. Australia (<http://www.pharmacyboard.gov.au/About/Statistics.aspx>, accessed 15 November 2016).
- Health at a glance: Asia/ Pacific (2016). Paris: The Organisation for Economic Co-operation and Development and World Health Organization (<http://www.oecd.org/health/health-at-a-glance-asia-pacific-23054964.htm>, accessed 2 December 2016).
- Global health expenditure database (2016) [online database]. Geneva: World Health Organization (<http://apps.who.int/nha/database>, accessed 25 November 2016).
- Data provided by country

WPR/2017/DHS/002

©World Health Organization 2017

Some rights reserved. This work is available under the CC BY-NC-SA 3.0 IGO licence.

# Pharmaceutical System

# BRUNEI DARUSSALAM


## SOCIOECONOMICS<sup>3</sup>

**417 000**  
Population

**77 years**  
Life Expectancy at Birth



**7%**  
Percentage of Adults Aged over 60 Years



**24%**  
Percentage of Children Aged below 15 Years

**US\$ 67 131.8**  
GDP / Capita (PPP)

## HUMAN RESOURCES<sup>1,2,3</sup>



**17.7**  
per 10 000 population

No. of Physicians



**0.17**  
per 1000 population

No. of Pharmacists<sup>a</sup>



**2.7**  
per 1000 population

Hospital Beds




**3.9**  
per capita


Doctor Consultations

## HEALTH EXPENDITURE<sup>3</sup>


**US\$ 1777.8**  
Total Health Expenditure / Capita (PPP)



Total Health Expenditure as a Share of GDP




Public vs Private Share of Total Health Expenditure



Composition of Total Health Expenditure

## PHARMACEUTICAL EXPENDITURE<sup>2</sup>

**US\$ 369.9**  
Total Pharmaceutical Expenditure / Capita (PPP)



Pharmaceutical Expenditure as a Share of Total Health Expenditure / Capita



Public vs Private Share of Total Pharmaceutical Expenditure

## PHARMACEUTICAL REGULATION

Regulatory Authority for Pharmaceuticals  
Brunei Darussalam Medicines Control Authority

Pharmaceutical Legislation  
Medicines Order 2007, Medicines (Licensing, Standard Provision and Fees) Regulations 2010, Medicines (Labelling) Regulations 2010, Poisons Act 1956 and Misuse of Drug Regulations

National Medicines Policy  
National Medicines Policy 2014

## PRICING

Agency that Sets Price  
None

Pricing Regulation in the Public Sector  
NO

Pricing Regulation in the Private Sector  
NO

Free Pricing?

YES

Price Negotiations?

YES

External Price Referencing?

YES

Internal Price Referencing?

YES

VAT on Medicines

NO

## PROCUREMENT / REIMBURSEMENT

Body Responsible for Selection of Products for Public Procurement/Reimbursement  
Drug Advisory Committee, Ministry of Health

Body Responsible for Health Technology Assessment  
No data available

**2145**  
No. of Registered Medicines

**1038**  
No. of Products on Essential Medicines List


**1311**  
No. of Products on Procurement List

No data available  
No. of Products on Reimbursement List

<sup>a</sup> Pharmaceutical personnel



# Pharmaceutical System Flowchart



## REFERENCES

- 1 World health statistics (2015) [online database]. Geneva: World Health Organization ([http://www.who.int/gho/publications/world\\_health\\_statistics/2015/en/](http://www.who.int/gho/publications/world_health_statistics/2015/en/), accessed 25 November 2016).
- 2 Health at a glance: Asia/ Pacific (2016). Paris: The Organisation for Economic Co-operation and Development and World Health Organization (<http://www.oecd.org/health/health-at-a-glance-asia-pacific-23054964.htm>, accessed 2 December 2016).
- 3 Data provided by country

WPR/2017/DHS/003

©World Health Organization 2017

Some rights reserved. This work is available under the CC BY-NC-SA 3.0 IGO licence.


## SOCIOECONOMICS<sup>1</sup>

**15 135 000**  
Population

**73 years**  
Life Expectancy at Birth



**8%**  
Percentage of Adults Aged over 60 Years



**31%**  
Percentage of Children Aged below 15 Years

**US\$ 3228.4**  
GDP / Capita (PPP)

## HUMAN RESOURCES<sup>1,2</sup>



**1.7**  
per 10 000 population

No. of Physicians



**0.14**  
per 1000 population

No. of Pharmacists<sup>a</sup>



**0.7**  
per 1000 population

Hospital Beds




**0.7**  
per capita


Doctor Consultations

## HEALTH EXPENDITURE<sup>3</sup>


**US\$ 183.2**  
Total Health Expenditure / Capita (PPP)



Total Health Expenditure as a Share of GDP




Public vs Private Share of Total Health Expenditure



Composition of Total Health Expenditure

## PHARMACEUTICAL EXPENDITURE<sup>2</sup>

**US\$ 80.7**  
Total Pharmaceutical Expenditure / Capita (PPP)



Pharmaceutical Expenditure as a Share of Total Health Expenditure / Capita



Public vs Private Share of Total Pharmaceutical Expenditure

## PHARMACEUTICAL REGULATION

Regulatory Authority for Pharmaceuticals  
Department of Drugs and Food, Ministry of Health

Pharmaceutical Legislation  
Law on the Management of Pharmaceuticals 2007

National Medicines Policy  
National Medicines Policy 2010

## PRICING

Agency that Sets Price  
None

Pricing Regulation in the Public Sector  
NO

Pricing Regulation in the Private Sector  
NO

Free Pricing?

YES

Price Negotiations?

YES

External Price Referencing?

YES

Internal Price Referencing?

YES

VAT on Medicines

10%

## PROCUREMENT / REIMBURSEMENT

Body Responsible for Selection of Products for Public Procurement/Reimbursement  
Ministry of Health

Body Responsible for Health Technology Assessment  
None


**16 920**  
No. of Registered Medicines

**770**  
No. of Products on Essential Medicines List

No data available  
No. of Products on Procurement List

No data available  
No. of Products on Reimbursement List

# Pharmaceutical System Flowchart



## REFERENCES

- 1 World health statistics (2015) [online database]. Geneva: World Health Organization ([http://www.who.int/gho/publications/world\\_health\\_statistics/2015/en/](http://www.who.int/gho/publications/world_health_statistics/2015/en/), accessed 25 November 2016).
- 2 Health at a glance: Asia/ Pacific (2016). Paris: The Organisation for Economic Co-operation and Development and World Health Organization (<http://www.oecd.org/health/health-at-a-glance-asia-pacific-23054964.htm>, accessed 2 December 2016).
- 3 Global health expenditure database (2016) [online database]. Geneva: World Health Organization (<http://apps.who.int/nha/database>, accessed 25 November 2016).

WPR/2017/DHS/004

©World Health Organization 2017

Some rights reserved. This work is available under the CC BY-NC-SA 3.0 IGO licence.

# Pharmaceutical System

# CHINA


## SOCIOECONOMICS <sup>1,2</sup>

**1 360 720 000**  
Population

**75 years**  
Life Expectancy at Birth



**14.8%**  
Percentage of Adults Aged over 60 Years



**16.6%**  
Percentage of Children Aged below 15 Years

**US\$ 13 166.7**  
GDP / Capita (PPP)

## HUMAN RESOURCES <sup>1,2</sup>



**17.3**  
per 10 000 population

No. of Physicians



**0.3**  
per 1000 population

No. of Pharmacists



**4.55**  
per 1000 population

Hospital Beds




**5.4**  
per capita


Doctor Consultations

## HEALTH EXPENDITURE <sup>2</sup>


**US\$ 730.5**  
Total Health Expenditure / Capita (PPP)



Total Health Expenditure as a Share of GDP




Public vs Private Share of Total Health Expenditure



Composition of Total Health Expenditure

## PHARMACEUTICAL EXPENDITURE <sup>2</sup>

**US\$ 288.1**  
Total Pharmaceutical Expenditure / Capita (PPP)



Pharmaceutical Expenditure as a Share of Total Health Expenditure / Capita



Public vs Private Share of Total Pharmaceutical Expenditure

## PHARMACEUTICAL REGULATION

Regulatory Authority for Pharmaceuticals  
China Food and Drug Administration

Pharmaceutical Legislation  
Drug Administration Law 2001

National Medicines Policy  
National Essential Medicines Policy 2009

## PRICING

Agency that Sets Price  
Pricing Bureau, under the National Development and Reform Commission

Pricing Regulation in the Public Sector **YES**

Pricing Regulation in the Private Sector **NO**

Free Pricing? **YES**

Price Negotiations? **YES**

External Price Referencing? **YES**

Internal Price Referencing? **YES**

VAT on Medicines **17%**

## PROCUREMENT / REIMBURSEMENT

Bodies Responsible for Selection of Products for Public Procurement/Reimbursement  
Ministry of Human Resources and Social Security and National Health and Family Planning Commission

Body Responsible for Health Technology Assessment  
China National Health Development Research Center


**168 000**  
No. of Registered Medicines

**520**  
No. of Products on Essential Medicines List

**Varies by Province**  
No. of Products on Procurement List

**2535**  
No. of Products on Reimbursement List

# Pharmaceutical System Flowchart



## REFERENCES

- 1 China Health and Family Planning Statistical Yearbook (2014). China: Peking Union Medical College Press.
- 2 Health at a glance: Asia/ Pacific (2016). Paris: The Organisation for Economic Co-operation and Development and World Health Organization (<http://www.oecd.org/health/health-at-a-glance-asia-pacific-23054964.htm>, accessed 2 December 2016).

WPR/2017/DHS/005

©World Health Organization 2017

Some rights reserved. This work is available under the CC BY-NC-SA 3.0 IGO licence.


## SOCIOECONOMICS<sup>1,2</sup>

**249 866 000**  
Population

**71 years**  
Life Expectancy at Birth



**8%**  
Percentage of Adults Aged over 60 Years



**29%**  
Percentage of Children Aged below 15 Years

**US\$ 10 517**  
GDP / Capita (PPP)

## HUMAN RESOURCES<sup>2</sup>



**3.2**  
per 10 000 population

No. of Physicians



**No data**

No. of Pharmacists



**0.6**  
per 1000 population

Hospital Beds




**No data**


Doctor Consultations

## HEALTH EXPENDITURE<sup>2</sup>


**US\$ 299.4**  
Total Health Expenditure / Capita (PPP)



Total Health Expenditure as a Share of GDP




Public vs Private Share of Total Health Expenditure



Composition of Total Health Expenditure

## PHARMACEUTICAL EXPENDITURE<sup>2</sup>

**US\$ 103.9**  
Total Pharmaceutical Expenditure / Capita (PPP)



Pharmaceutical Expenditure as a Share of Total Health Expenditure / Capita



Public vs Private Share of Total Pharmaceutical Expenditure

## PHARMACEUTICAL REGULATION

Regulatory Authority for Pharmaceuticals  
National Agency for Drug and Food Control

Pharmaceutical Legislation  
Regulation 1010/2008, Health Act of Republic of Indonesia No. 36/2009

National Medicines Policy  
National Medicines Policy 2006

## PRICING

Agency that Sets Price  
Ministry of Health

Pricing Regulation in the Public Sector **YES**

Pricing Regulation in the Private Sector **YES**

Free Pricing?

**YES**

Price Negotiations?

**YES**

External Price Referencing?

**NO**

Internal Price Referencing?

**NO**

VAT on Medicines

**10%**

## PROCUREMENT / REIMBURSEMENT

Body Responsible for Selection of Products for Public Procurement/Reimbursement  
National Committee on Selection and Use of Essential Medicines

Body Responsible for Health Technology Assessment  
None


**18 000**  
No. of Registered Medicines

**No data available**  
No. of Products on Essential Medicines List

**720**  
No. of Products on Procurement List

**923**  
No. of Products on Reimbursement List

# Pharmaceutical System Flowchart



## REFERENCES

- World health statistics (2015) [online database]. Geneva: World Health Organization ([http://www.who.int/gho/publications/world\\_health\\_statistics/2015/en/](http://www.who.int/gho/publications/world_health_statistics/2015/en/), accessed 25 November 2016).
- Health at a glance: Asia/ Pacific (2016). Paris: The Organisation for Economic Co-operation and Development and World Health Organization (<http://www.oecd.org/health/health-at-a-glance-asia-pacific-23054964.htm>, accessed 2 December 2016).

WPR/2017/DHS/006

©World Health Organization 2017

Some rights reserved. This work is available under the CC BY-NC-SA 3.0 IGO licence.

# Pharmaceutical System

# REPUBLIC OF KOREA


## SOCIOECONOMICS<sup>1</sup>

**49 263 000**  
Population

**82 years**  
Life Expectancy at Birth



**17%**  
Percentage of Adults Aged over 60 Years



**15%**  
Percentage of Children Aged below 15 Years

**US\$ 34 321.6**  
GDP / Capita (PPP)

## HUMAN RESOURCES<sup>2</sup>



**22.4**  
per 10 000 population

No. of Physicians



**1.28**  
per 1000 population

No. of Pharmacists



**10.3**  
per 1000 population

Hospital Beds




**14.6**  
per capita


Doctor Consultations

## HEALTH EXPENDITURE<sup>2</sup>


**US\$ 2530.6**  
Total Health Expenditure / Capita (PPP)



Total Health Expenditure as a Share of GDP




Public vs Private Share of Total Health Expenditure




Composition of Total Health Expenditure

## PHARMACEUTICAL EXPENDITURE<sup>2</sup>

**US\$ 583.4**  
Total Pharmaceutical Expenditure / Capita (PPP)



Pharmaceutical Expenditure as a Share of Total Health Expenditure / Capita



Public vs Private Share of Total Pharmaceutical Expenditure

## PHARMACEUTICAL REGULATION

Regulatory Authority for Pharmaceuticals  
Ministry of Food and Drug Safety

Pharmaceutical Legislation  
Pharmaceutical Affairs Act

National Medicines Policy  
National Medicine Policy Plan

## PRICING

Agency that Sets Price  
Ministry of Health and Welfare

Pricing Regulation in the Public Sector **YES**

Pricing Regulation in the Private Sector **NO**

Free Pricing?

**NO**

Price Negotiations?

**YES**

External Price Referencing?

**YES**

Internal Price Referencing?

**NO**

VAT on Medicines

**10%**

## PROCUREMENT / REIMBURSEMENT

Body Responsible for Selection of Products for Public Procurement/Reimbursement  
Health Insurance and Review and Assessment Service

Body Responsible for Health Technology Assessment  
National Evidence-based Healthcare Collaborating Agency

**39 847**  
No. of Registered Medicines


No data available  
No. of Products on Essential Medicines List

No data available  
No. of Products on Procurement List

**17 798**  
No. of Products on Reimbursement List



# Pharmaceutical System Flowchart



## REFERENCES

- World health statistics (2015) [online database]. Geneva: World Health Organization ([http://www.who.int/gho/publications/world\\_health\\_statistics/2015/en/](http://www.who.int/gho/publications/world_health_statistics/2015/en/), accessed 25 November 2016).
- Health at a glance: Asia/ Pacific (2016). Paris: The Organisation for Economic Co-operation and Development and World Health Organization (<http://www.oecd.org/health/health-at-a-glance-asia-pacific-23054964.htm>, accessed 2 December 2016).

WPR/2017/DHS/007

©World Health Organization 2017

Some rights reserved. This work is available under the CC BY-NC-SA 3.0 IGO licence.

# Pharmaceutical System

# LAO PEOPLE'S DEMOCRATIC REPUBLIC

## SOCIOECONOMICS<sup>1,3</sup>

**6 492 228**

Population


**64 years**

Life Expectancy at Birth



**6.5%**

Percentage of Adults Aged over 60 Years



**32%**

Percentage of Children Aged below 15 Years

**US\$ 5278.2**

GDP / Capita (PPP)

## HUMAN RESOURCES<sup>2,3</sup>



**29**

per 10 000 population

No. of Physicians



**0.19**

per 1000 population

No. of Pharmacists<sup>a</sup>



**1.5**

per 1000 population

Hospital Beds




**No data**

Doctor Consultations


## HEALTH EXPENDITURE<sup>3</sup>

**US\$ 98.5**


Total Health Expenditure / Capita (PPP)



Total Health Expenditure as a Share of GDP



Public vs Private Share of Total Health Expenditure




Composition of Total Health Expenditure


## PHARMACEUTICAL EXPENDITURE<sup>3</sup>

**US\$ 27.3**

Total Pharmaceutical Expenditure / Capita (PPP)



Pharmaceutical Expenditure as a Share of Total Health Expenditure / Capita



Public vs Private Share of Total Pharmaceutical Expenditure

## PHARMACEUTICAL REGULATION

Regulatory Authority for Pharmaceuticals

Food and Drug Department, Ministry of Health

Pharmaceutical Legislation

Law on Drugs and Medical Products 2011, Regulation Governing Drug Registration 2003

National Medicines Policy

National Medicines Policy 2003

## PRICING

Agency that Sets Price

Ministry of Health (for public sector)

Pricing Regulation in the Public Sector

**YES**

Pricing Regulation in the Private Sector

**NO**

Free Pricing?

**YES**

Price Negotiations?

**YES**

External Price Referencing?

**YES**

Internal Price Referencing?

**YES**

VAT on Medicines

**10%**

## PROCUREMENT / REIMBURSEMENT

Body Responsible for Selection of Products for Public Procurement/Reimbursement

Public Hospital Pharmacy Division, Food and Drug Department, Ministry of Health

Body Responsible for Health Technology Assessment

Medical Product Supply Center

**1521**

No. of Registered Medicines

**374**

No. of Products on Essential Medicines List


**746**

No. of Products on Procurement List

**374**

No. of Products on Reimbursement List

# Pharmaceutical System Flowchart



## REFERENCES

- 1 World health statistics (2015) [online database]. Geneva: World Health Organization ([http://www.who.int/gho/publications/world\\_health\\_statistics/2015/en/](http://www.who.int/gho/publications/world_health_statistics/2015/en/), accessed 25 November 2016).
- 2 Health at a glance: Asia/ Pacific (2016). Paris: The Organisation for Economic Co-operation and Development and World Health Organization (<http://www.oecd.org/health/health-at-a-glance-asia-pacific-23054964.htm>, accessed 2 December 2016).
- 3 Data provided by country

WPR/2017/DHS/008

©World Health Organization 2017

Some rights reserved. This work is available under the CC BY-NC-SA 3.0 IGO licence.


## SOCIOECONOMICS<sup>1</sup>

**29 717 000**  
Population

**74 years**  
Life Expectancy at Birth



**9%**  
Percentage of Adults Aged over 60 Years



**26%**  
Percentage of Children Aged below 15 Years

**US\$ 24 951.1**  
GDP / Capita (PPP)

## HUMAN RESOURCES<sup>2</sup>

**12.6**  
per 10 000 population  
**No. of Physicians**



**0.34**  
per 1000 population  
**No. of Pharmacists<sup>a</sup>**



**1.9**  
per 1000 population  
**Hospital Beds**






**3.5**  
per capita  
**Doctor Consultations**





## HEALTH EXPENDITURE<sup>2</sup>

**US\$ 1040.2**  
Total Health Expenditure / Capita (PPP)



## PHARMACEUTICAL EXPENDITURE<sup>2</sup>

**US\$ 198.8**  
Total Pharmaceutical Expenditure / Capita (PPP)



## PHARMACEUTICAL REGULATION

**Regulatory Authority for Pharmaceuticals**  
National Pharmaceutical Regulatory Agency

**Pharmaceutical Legislation**  
Poisons Act 1952, Sale of Drugs Act 1952, Control of Drugs and Cosmetics Regulations 1984

**National Medicines Policy**  
National Medicines Policy 2012

## PRICING

**Agency that Sets Price**  
Ministry of Domestic Trade, Cooperatives and Consumerism<sup>b</sup>

**Pricing Regulation in the Public Sector** **YES**

**Pricing Regulation in the Private Sector** **NO**

**Free Pricing?**  
**YES**

**Price Negotiations?**  
**YES**

**External Price Referencing?**  
**YES**

**Internal Price Referencing?**  
**YES**

**VAT on Medicines**  
**6%<sup>c</sup>**

## PROCUREMENT / REIMBURSEMENT

**Body Responsible for Selection of Products for Public Procurement/Reimbursement**  
Pharmaceutical Services Division, Ministry of Health

**Body Responsible for Health Technology Assessment**  
Pharmaceutical Services Division/Medical Development Division, Ministry of Health

**10 680**  
No. of Registered Medicines


**4300**  
No. of Products on Essential Medicines List

**1695<sup>d</sup>**  
No. of Products on Procurement List

**1695**  
No. of Products on Reimbursement List

<sup>a</sup> Pharmaceutical personnel  
<sup>b</sup> Monitoring function only  
<sup>c</sup> Zero for prescription drugs and items listed on the National Essential Medicines List  
<sup>d</sup> Number of international nonproprietary names of medicines listed

# Pharmaceutical System Flowchart



## REFERENCES

- 1 World health statistics (2015) [online database]. Geneva: World Health Organization ([http://www.who.int/gho/publications/world\\_health\\_statistics/2015/en/](http://www.who.int/gho/publications/world_health_statistics/2015/en/), accessed 25 November 2016).
- 2 Health at a glance: Asia/ Pacific (2016). Paris: The Organisation for Economic Co-operation and Development and World Health Organization (<http://www.oecd.org/health/health-at-a-glance-asia-pacific-23054964.htm>, accessed 2 December 2016).

WPR/2017/DHS/009

©World Health Organization 2017

Some rights reserved. This work is available under the CC BY-NC-SA 3.0 IGO licence.

# Pharmaceutical System

# MONGOLIA


## SOCIOECONOMICS<sup>1,3</sup>

**3 119 935**  
Population

**68 years**  
Life Expectancy at Birth



**6%**  
Percentage of Adults Aged over 60 Years



**27%**  
Percentage of Children Aged below 15 Years

**US\$ 11 945.7**  
GDP / Capita (PPP)

## HUMAN RESOURCES<sup>1,2</sup>



**28.4**  
per 10 000 population

No. of Physicians



**0.6**  
per 1000 population

No. of Pharmacists



**7**  
per 1000 population

Hospital Beds




**6.1**  
per capita


Doctor Consultations

## HEALTH EXPENDITURE<sup>2</sup>


**US\$ 565.1**  
Total Health Expenditure / Capita (PPP)



Total Health Expenditure as a Share of GDP




Public vs Private Share of Total Health Expenditure



Composition of Total Health Expenditure

## PHARMACEUTICAL EXPENDITURE<sup>2</sup>

**US\$ 147.2**  
Total Pharmaceutical Expenditure / Capita (PPP)



Pharmaceutical Expenditure as a Share of Total Health Expenditure / Capita



Public vs Private Share of Total Pharmaceutical Expenditure

## PHARMACEUTICAL REGULATION

Regulatory Authority for Pharmaceuticals

Ministry of Health, Center for Health Development and General Agency for State Inspection

Pharmaceutical Legislation

Law on Medicines and Medical Devices 2010

National Medicines Policy

National Medicines Policy 2014

## PRICING

Agency that Sets Price  
None

Pricing Regulation in the Public Sector

NO

Pricing Regulation in the Private Sector

NO

Free Pricing?

YES

Price Negotiations?

NO

External Price Referencing?

NO

Internal Price Referencing?

NO

VAT on Medicines

10%

## PROCUREMENT / REIMBURSEMENT

Body Responsible for Selection of Products for Public Procurement/Reimbursement

National Health Insurance Council

Body Responsible for Health Technology Assessment

Technical Evaluation Committee, Ministry of Health


**4688**  
No. of Registered Medicines

**486**  
No. of Products on Essential Medicines List

No data available  
No. of Products on Procurement List

**190**  
No. of Products on Reimbursement List

# Pharmaceutical System Flowchart



## REFERENCES

- World health statistics (2015) [online database]. Geneva: World Health Organization ([http://www.who.int/gho/publications/world\\_health\\_statistics/2015/en/](http://www.who.int/gho/publications/world_health_statistics/2015/en/), accessed 25 November 2016).
- Health at a glance: Asia/ Pacific (2016). Paris: The Organisation for Economic Co-operation and Development and World Health Organization (<http://www.oecd.org/health/health-at-a-glance-asia-pacific-23054964.htm>, accessed 2 December 2016).
- Data provided by country

WPR/2017/DHS/010

©World Health Organization 2017

Some rights reserved. This work is available under the CC BY-NC-SA 3.0 IGO licence.

# Pharmaceutical System

# NEW ZEALAND


## SOCIOECONOMICS<sup>1,4</sup>

**4 647 300**  
Population

**82 years**  
Life Expectancy at Birth



**20%**  
Percentage of Adults Aged over 60 Years



**20%**  
Percentage of Children Aged below 15 Years

**US\$ 37 340**  
GDP / Capita (PPP)

## HUMAN RESOURCES<sup>2,4</sup>



**28.4**  
per 10 000 population

No. of Physicians



**0.77**  
per 1000 population

No. of Pharmacists



**2.8**  
per 1000 population

Hospital Beds




**3.7**  
per capita


Doctor Consultations

## HEALTH EXPENDITURE<sup>2,3</sup>


**US\$ 4018.3**  
Total Health Expenditure / Capita (PPP)



Total Health Expenditure as a Share of GDP




Public vs Private Share of Total Health Expenditure



Composition of Total Health Expenditure

## PHARMACEUTICAL EXPENDITURE<sup>2</sup>

**US\$ 391.6**  
Total Pharmaceutical Expenditure / Capita (PPP)



Pharmaceutical Expenditure as a Share of Total Health Expenditure / Capita



Public vs Private Share of Total Pharmaceutical Expenditure

## PHARMACEUTICAL REGULATION

Regulatory Authority for Pharmaceuticals  
Medicines and Medical Devices Safety Authority

Pharmaceutical Legislation  
The Medicines Act 1981, The Medicines Regulations 1984

National Medicines Policy  
Medicines New Zealand 2007

## PRICING

Agency that Sets Price  
Pharmaceutical Management Agency

Pricing Regulation in the Public Sector  
**NO**

Pricing Regulation in the Private Sector  
**NO**

Free Pricing?

**NO**

Price Negotiations?

**YES**

External Price Referencing?

**NO**

Internal Price Referencing?

**YES**

VAT on Medicines

**15% GST**

## PROCUREMENT / REIMBURSEMENT

Body Responsible for Selection of Products for Public Procurement/Reimbursement  
Pharmaceutical Management Agency

Body Responsible for Health Technology Assessment  
Ministry of Health

**6262**  
No. of Registered Medicines

more than **4500<sup>a</sup>**  
No. of Products on Essential Medicines List


more than **4500**  
No. of Products on Procurement List

more than **4500**  
No. of Products on Reimbursement List

<sup>a</sup> Products on the Pharmaceutical Schedule



# Pharmaceutical System Flowchart



## REFERENCES

- World health statistics (2015) [online database]. Geneva: World Health Organization ([http://www.who.int/gho/publications/world\\_health\\_statistics/2015/en/](http://www.who.int/gho/publications/world_health_statistics/2015/en/), accessed 25 November 2016).
- Health at a glance: Asia/ Pacific (2016). Paris: The Organisation for Economic Co-operation and Development and World Health Organization (<http://www.oecd.org/health/health-at-a-glance-asia-pacific-23054964.htm>, accessed 2 December 2016).
- The World Bank (2016). Databank [website]. (<http://databank.worldbank.org/data/home.aspx>, accessed 25 November 2016).
- Data provided by country

WPR/2017/DHS/011

©World Health Organization 2017

Some rights reserved. This work is available under the CC BY-NC-SA 3.0 IGO licence.


## SOCIOECONOMICS<sup>1</sup>

**102 965 300**  
Population

**69 years**  
Life Expectancy at Birth



**8%**  
Percentage of Adults Aged over 60 Years



**32%**  
Percentage of Children Aged below 15 Years

**US\$ 6982.4**  
GDP / Capita (PPP)

## HUMAN RESOURCES<sup>1,3</sup>



**3.56**  
per 10 000 population

No. of Physicians



**4.19**  
per 1000 population

No. of Pharmacists



**1.2**  
per 1000 population

Hospital Beds




No data available


Doctor Consultations

## HEALTH EXPENDITURE<sup>2</sup>


**US\$ 328.9**  
Total Health Expenditure / Capita (PPP)



Total Health Expenditure as a Share of GDP




Public vs Private Share of Total Health Expenditure




Composition of Total Health Expenditure

## PHARMACEUTICAL EXPENDITURE<sup>2</sup>

**US\$ 109.4**  
Total Pharmaceutical Expenditure / Capita (PPP)



Pharmaceutical Expenditure as a Share of Total Health Expenditure / Capita



Public vs Private Share of Total Pharmaceutical Expenditure

## PHARMACEUTICAL REGULATION

Regulatory Authority for Pharmaceuticals

Food and Drug Administration,  
Dangerous Drugs Board

Pharmaceutical Legislation

Generics Act 1988, Consumer Act of the Philippines 1992, Universally Accessible Cheaper and Quality Medicines Act 2008, Food and Drug Administration Act 2009, Expanded Senior Citizens Act 2011, Philippine Pharmacy Act 2016

National Medicines Policy

Philippine Medicines Policy

## PRICING

Agency that Sets Price

Department of Health

Pricing Regulation in the Public Sector

YES

Pricing Regulation in the Private Sector

YES<sup>a</sup>

Free Pricing?

NO

Price Negotiations?

YES

External Price Referencing?

YES

Internal Price Referencing?

YES

VAT on Medicines

12%

## PROCUREMENT / REIMBURSEMENT

Body Responsible for Selection of Products for Public Procurement/Reimbursement

Formulary Executive Council,  
Department of Health

Body Responsible for Health Technology Assessment

Department of Health


**19 381**  
No. of Registered Medicines

**676**  
No. of Products on Essential Medicines List

**676**  
No. of Products on Procurement List

**676**  
No. of Products on Reimbursement List

# Pharmaceutical System Flowchart



## REFERENCES

- 1 Philippine Statistics Authority (2015). (<http://psa.gov.ph>, Accessed 15 November 2016).
- 2 Health at a glance: Asia/ Pacific (2016). Paris: The Organisation for Economic Co-operation and Development and World Health Organization (<http://www.oecd.org/health/health-at-a-glance-asia-pacific-23054964.htm>, accessed 2 December 2016).
- 3 Department of Health – Health Human Resources Development Bureau (2014). (<http://www.doh.gov.ph/node/655>, Accessed 15 November 2016).

WPR/2017/DHS/012

©World Health Organization 2017

Some rights reserved. This work is available under the CC BY-NC-SA 3.0 IGO licence.

# Pharmaceutical System

# SINGAPORE


## SOCIOECONOMICS<sup>1,2,3</sup>

**5 470 000**  
Population

**83 years**  
Life Expectancy at Birth



**17%**  
Percentage of Adults Aged over 60 Years



**16%**  
Percentage of Children Aged below 15 Years

**US\$ 80 191.5**  
GDP / Capita (PPP)

## HUMAN RESOURCES<sup>3</sup>

**21**  
per 10 000 population  
No. of Physicians



**0.5**  
per 1000 population  
No. of Pharmacists



**2.2**  
per 1000 population  
Hospital Beds




**1.7**  
per capita  
Doctor Consultations




## HEALTH EXPENDITURE<sup>2,3</sup>

**US\$ 2538**  
Total Health Expenditure / Capita (PPP)


**4.3%**  
Total Health Expenditure as a share of GDP



**54.2% Public** / **45.8% Private**  
Public vs Private Share of Total Health Expenditure




**43.8% General Government** / **30.7% Out-of-Pocket** / **15.1% Voluntary Health Care Payment<sup>a</sup>** / **10.4% Social Health Care<sup>b</sup>**  
Composition of Total Health Expenditure



## PHARMACEUTICAL EXPENDITURE

**US\$ No data available**  
Total Pharmaceutical Expenditure / Capita (PPP)

**No data available**  
Pharmaceutical Expenditure as a Share of Total Health Expenditure / Capita



**No data available**  
Public vs Private Share of Total Pharmaceutical Expenditure

## PHARMACEUTICAL REGULATION

Regulatory Authority for Pharmaceuticals  
Health Sciences Authority

Pharmaceutical Legislation  
Health Products Act

National Medicines Policy  
No Formal National Medicines Policy

## PRICING

Agency that Sets Price  
None

Pricing Regulation in the Public Sector  
**NO**

Pricing Regulation in the Private Sector  
**NO**

Free Pricing?  
**YES**

Price Negotiations?  
**YES**

External Price Referencing?  
**NO**

Internal Price Referencing?  
**NO**

VAT on Medicines  
**NO**

## PROCUREMENT / REIMBURSEMENT

Body Responsible for Selection of Products for Public Procurement/Reimbursement  
Drug Advisory Committee, Ministry of Health

Body Responsible for Health Technology Assessment  
Agency for Care Effectiveness

**5500**  
No. of Registered Medicines

**No data available**  
No. of Products on Essential Medicines List


**590**  
No. of Products on Procurement List

**1040**  
No. of Products on Reimbursement List

<sup>a</sup> Health-care expenditures paid out from voluntary or private sources

<sup>b</sup> Combined compulsory medical savings accounts, social health insurance, and other government-supported schemes not classified elsewhere

# Pharmaceutical System Flowchart



## REFERENCES

- 1 World health statistics (2015) [online database]. Geneva: World Health Organization ([http://www.who.int/gho/publications/world\\_health\\_statistics/2015/en/](http://www.who.int/gho/publications/world_health_statistics/2015/en/), accessed 25 November 2016).
- 2 The World Bank (2016). Databank [website]. (<http://databank.worldbank.org/data/home.aspx>, accessed 25 November 2016).
- 3 Data provided by country

WPR/2017/DHS/013

©World Health Organization 2017

Some rights reserved. This work is available under the CC BY-NC-SA 3.0 IGO licence.

# Pharmaceutical System

# THAILAND


## SOCIOECONOMICS<sup>1,3</sup>

**65 729 000**  
Population

**75 years**  
Life Expectancy at Birth



**14%**  
Percentage of Adults Aged over 60 Years



**18%**  
Percentage of Children Aged below 15 Years

**US\$ 15 346.7**  
GDP / Capita (PPP)

## HUMAN RESOURCES<sup>2,3</sup>



**4.9**  
per 10 000 population

No. of Physicians



**0.19**  
per 1000 population

No. of Pharmacists



**2.3**  
per 1000 population

Hospital Beds




**2.1**  
per capita


Doctor Consultations

## HEALTH EXPENDITURE<sup>3</sup>


**US\$ 658.2**  
Total Health Expenditure / Capita (PPP)



Total Health Expenditure as a Share of GDP




Public vs Private Share of Total Health Expenditure



Composition of Total Health Expenditure

## PHARMACEUTICAL EXPENDITURE<sup>2,3</sup>

**US\$ 599.84**  
Total Pharmaceutical Expenditure / Capita (PPP)



Pharmaceutical Expenditure as a Share of Total Health Expenditure / Capita



Public vs Private Share of Total Pharmaceutical Expenditure

## PHARMACEUTICAL REGULATION

Regulatory Authority for Pharmaceuticals

Food and Drug Administration

Pharmaceutical Legislation

Drug Act 1967

National Medicines Policy

National Drug Policy 1981

## PRICING

Agency that Sets Price

National Essential Drugs List Subcommittee

Pricing Regulation in the Public Sector

**YES**

Pricing Regulation in the Private Sector

**NO**

Free Pricing?

**YES**

Price Negotiations?

**YES**

External Price Referencing?

**YES**

Internal Price Referencing?

**YES**

VAT on Medicines

**7%**

## PROCUREMENT / REIMBURSEMENT

Body Responsible for Selection of Products for Public Procurement/Reimbursement

National Essential Drugs List Subcommittee

**22 667**  
No. of Registered Medicines

**766<sup>a</sup>**  
No. of Products on Essential Medicines List

Body Responsible for Health Technology Assessment

Health Intervention and Technology Assessment Program


**106<sup>b</sup>**  
No. of Products on Procurement List

**766<sup>a</sup>**  
No. of Products on Reimbursement List

<sup>a</sup> Number of international nonproprietary names of medicines listed

<sup>b</sup> Number of international nonproprietary names of medicines on Central Procurement List for Universal Coverage Scheme and Social Security Scheme

# Pharmaceutical System Flowchart



## REFERENCES

- 1 The World Bank (2016). Databank [website]. (<http://databank.worldbank.org/data/home.aspx>, accessed 25 November 2016).
- 2 Health at a glance: Asia/ Pacific (2016). Paris: The Organisation for Economic Co-operation and Development and World Health Organization (<http://www.oecd.org/health/health-at-a-glance-asia-pacific-23054964.htm>, accessed 2 December 2016).
- 3 Data provided by country

WPR/2017/DHS/014

©World Health Organization 2017

Some rights reserved. This work is available under the CC BY-NC-SA 3.0 IGO licence.

# Pharmaceutical System

# VIET NAM


## SOCIOECONOMICS<sup>1</sup>

**91 680 000**  
Population

**76 years**  
Life Expectancy  
at Birth



**10%**  
Percentage  
of Adults  
Aged over  
60 Years



**23%**  
Percentage  
of Children  
Aged below  
15 Years

**US\$ 5525.8**  
GDP / Capita (PPP)

## HUMAN RESOURCES<sup>1,2</sup>

**11.9**  
per 10 000  
population  
**No. of Physicians**



**No data available**  
**No. of Pharmacists**



**2.5**  
per 1000  
population  
**Hospital Beds**






**2.3**  
per capita  
**Doctor Consultations**





## HEALTH EXPENDITURE<sup>2</sup>

**US\$ 390.5**  
Total Health Expenditure /  
Capita (PPP)



## PHARMACEUTICAL EXPENDITURE<sup>2</sup>

**US\$ 123.7**  
Total Pharmaceutical  
Expenditure / Capita (PPP)



## PHARMACEUTICAL REGULATION

**Regulatory Authority for Pharmaceuticals**  
Drug Administration of Vietnam

**Pharmaceutical Legislation**  
The Pharmacy Law (No. 105/2016/QH13)

**National Medicines Policy**  
National Strategy for Pharmaceutical  
Sector Development

## PRICING

**Agency that Sets Price**  
Ministry of Health, together with  
Ministry of Finance<sup>a</sup>

**Pricing Regulation  
in the Public Sector** **YES**

**Pricing Regulation  
in the Private Sector** **YES**

**Free Pricing?**  
**YES**

**Price Negotiations?**  
**YES**

**External Price Referencing?**  
**YES**

**Internal Price Referencing?**  
**YES**

**VAT on Medicines**  
**5%**

## PROCUREMENT / REIMBURSEMENT

**Body Responsible for Selection  
of Products for Public  
Procurement/Reimbursement**  
Department of Health  
Insurance, Ministry of Health

**Body Responsible for Health  
Technology Assessment**  
Health Strategy and  
Policy Institute

**45 000**  
No. of Registered  
Medicines

**466**  
No. of Products on  
Essential Medicines List


**100<sup>b</sup>**  
No. of Products on  
Procurement List

**900<sup>c</sup>**  
No. of Products on  
Reimbursement List

<sup>a</sup> Price control function only  
<sup>b</sup> For centralized procurement only  
<sup>c</sup> Active pharmacological ingredients



# Pharmaceutical System Flowchart



## REFERENCES

- World health statistics (2015) [online database]. Geneva: World Health Organization ([http://www.who.int/gho/publications/world\\_health\\_statistics/2015/en/](http://www.who.int/gho/publications/world_health_statistics/2015/en/), accessed 25 November 2016).
- Health at a glance: Asia/ Pacific (2016). Paris: The Organisation for Economic Co-operation and Development and World Health Organization (<http://www.oecd.org/health/health-at-a-glance-asia-pacific-23054964.htm>, accessed 2 December 2016).
- Data provided by country

WPR/2017/DHS/015

©World Health Organization 2017

Some rights reserved. This work is available under the CC BY-NC-SA 3.0 IGO licence.







WHO Western Pacific Region  
PUBLICATION



ISBN-13

978 92 9061 848 5